Fucosidosis
文献摘要
Clinical characteristics Fucosidosis is characterized by developmental delay, intellectual disability, psychomotor regression and cognitive decline, coarse facial features, recurrent respiratory infections, and musculoskeletal manifestations (kyphoscoliosis, joint contractures). Radiographs show variable features of dysostosis multiplex. Dermatologic manifestations include telangiectases and angiokeratoma. Ophthalmologic and cardiac manifestations and hypergonadotropic hypogonadism are common. Seizures, hepatosplenomegaly, hearing loss, and hernias are also reported. Phenotype is variable and has been categorized as more severe (type I) and less severe (type II). Individuals with type I fucosidosis typically die prior to age ten years due to respiratory infections and neurologic deterioration; those with type II fucosidosis can live into adulthood. Diagnosis/testing The diagnosis of fucosidosis is established in a proband with biallelic pathogenic variants in FUCA1 identified by molecular genetic testing or reduced alpha-L-fucosidase enzyme activity in leukocytes. Management Targeted therapy: Hematopoietic stem cell transplantation (HSCT) is considered if the diagnosis is established early before central nervous system deterioration. To date, very few individuals with fucosidosis have undergone HSCT. Supportive care: Developmental and educational support; treatment of spasticity per orthopedist / physical medicine and rehabilitation specialist; physical therapy and occupational therapy including stretching; hypersalivation management; analgesia and palliative care support for pain; management of recurrent infections and poor respiratory clearance per pulmonologist; feeding therapy and gastrostomy tube as needed for poor weight gain; specialty management for orthopedic, ocular, cardiac, and endocrine manifestations; standard treatment of seizures per neurologist; hearing aids as needed; surgical management of umbilical hernia as needed; transitional care plans; family and social work support. Surveillance: Annual developmental assessment, neurology evaluation, and behavioral assessment; physical medicine and occupational and physical therapy assessment of mobility and self-help skills; assessment of pain, respiratory status, feeding, nutrition, and growth every six to 12 months; assessment by orthopedist for contractures and scoliosis as needed; ophthalmology evaluation annually or as needed; clinical cardiology assessment with electrocardiogram and echocardiogram every six to 12 months; assessment for hypogonadotropic hypogonadism including growth evaluation in childhood, puberty, and at adulthood; audiology evaluation annually; assessment of family needs at each visit. Evaluation of relatives at risk: Clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures. Genetic counseling Fucosidosis is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a FUCA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the FUCA1 pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.